NYU Langone Health

Patients Taking Anti-Inflammatory Drugs Respond Less Well to COVID-19 Vaccine

Newswise — One-quarter of people who take the drug methotrexate for common immune system disorders — from rheumatoid arthritis to multiple sclerosis — mount a weaker immune response to a COVID-19 vaccine, a new study shows.

Published (online May 25) recently in Annals of the Rheumatic Diseases, the study addressed disorders that result when the immune system, meant to fight disease and drive healing, is triggered abnormally. This in turn causes inflammation, the pain and swelling that come as immune cells rush into damaged or infected tissue, but often in the wrong amount or context. Called immune-mediated inflammatory disorders, they are typically treated with drugs that reduce inflammation, including methotrexate.

Led by researchers at NYU Grossman School of Medicine, the new study looked specifically at patients’ responses to the Pfizer-BioNTech mRNA COVID-19 vaccine, which they measured by looking at the antibodies produced in each patient by the vaccine. Once injected into the body, vaccine ingredients are meant to trigger the production of antibodies, immune proteins that specifically glom onto this viral target protein, disabling it and tagging it for removal from the body.

The lower antibody response in patients who take methotrexate does not necessarily mean that these patients are not protected against COVID-19, cautions co-first study author Rebecca Haberman, MD, clinical instructor in the Department of Medicine at NYU Langone Health.

“It is most important to state that patients should not be concerned about our study findings as the majority of patients with immune system disorders are responding well to the mRNA vaccines,” Dr. Haberman says. “It is also possible that methotrexate is delaying, rather than preventing, an adequate immune response against COVID-19.”

Researchers have known that rheumatoid arthritis patients who take methotrexate have a reduced response to seasonal flu vaccines. Because mRNA vaccines use a new mechanism of action that patients with these common immune disorders have not seen before, the researchers wanted to determine how well these patients are protected.

The research was conducted at NYU Langone and at Friedrich-Alexander University Erlangen Nuremberg in Germany and enrolled healthy people and patients treated for common immune-mediated disorders, including rheumatoid arthritis, psoriatic arthritis and psoriasis. Study participants received two doses of Pfizer-BioNTech mRNA COVID-19 vaccine. The researchers analyzed blood samples to determine the amount of antibodies patients produced after receiving the vaccine and measured the activation of key immune system cells, including CD8 killer T cells, which are generated as part of the body’s immune response.

The researchers found that over 90 percent of healthy subjects and patients taking drugs other than methotrexate to control inflammation in both the New York and German study groups mounted strong antibody responses. Patients with immune-mediated inflammatory disorders who were taking methotrexate achieved an adequate response in only 62 percent of cases. Similarly, while healthy patients and those with common immune disorders who were taking anti-inflammatory drugs other than methotrexate produced CD8 T cells, patients taking methotrexate did not show an increase in CD8 T cell activation after vaccination.

“More research is needed to understand why such a significant proportion of people with common immune disorders who take methotrexate have deficiencies in mounting an antibody and cellular response,” says study co-senior author Jose U. Scher, MD, an associate professor in the Department of Medicine at NYU Langone. “This may not necessarily mean that the vaccine is not efficacious, but that alternate vaccine strategies need to be investigated.”

These alternate vaccine strategies include potentially discontinuing methotrexate during the time these patients receive the vaccine, changing the dosage of methotrexate or possibly administering a booster shot to the vaccine, says Dr. Scher, who is also director of the Psoriatic Arthritis Center at NYU Langone. The research team is currently leading studies to determine the best course of action for these patients.

This work was supported by National Institutes of Health grants R01 AR074500, T32 AR069515, and UM1 AI148574; a Rheumatology Research Foundation Scientist Development Award; the Bloomberg Philanthropies COVID-19 Initiative; the Pfizer COVID-19 Competitive Grant Program; The Beatrice Snyder Foundation; and The Riley Family Foundation.

Dr. Scher has served as a consultant for Janssen, Novartis, Pfizer, Bristol Myers Squibb, Sanofi and UCB, and Abbvie, and he has received funding for investigator-initiated studies from Novartis, Sanofi, Pfizer and Janssen. Dr. Haberman has received consulting fees from Janssen. Study co-investigators Peter M. Izmirly, MD, has received consulting fees from GSK and Momenta/Janssen; and Steven B. Abramson, MD, has received grants from Johnson and Johnson. Study co-corresponding author Mark J. Mulligan, MD, has received grants from Eli Lilly, Pfizer, and Sanofi and personal fees from Meissa Vaccines. All of these relationships are being managed in accordance with the policies and procedures of NYU Langone.

In addition to Drs. Scher, Haberman, Izmirly, Abramson, and Mulligan, other NYU Langone investigators are co-first authors Ramin Herati, MD, and Marie Samanovic-Golden, MD; and study co-investigators Rebecca B. Blank, MD, PhD; Michael Tuen, PhD; Sergei B. Koralov, PhD; Joseph R. Allen; Rochelle L. Castillo, MD; Amber R. Cornelius; Paula Rackoff, MD; Gary E. Solomon, MD; Samrachana Adhikari, PhD; Natalie E. Azar, MD; Pamela Rosenthal, MD; Jonathan Samuels, MD; Brian D. Golden, MD; and Soumya M. Reddy, MD. Other researchers involved in the study are co-corresponding author Georg Schett, MD, PhD; co-first author David Simon, MD; and study co-investigators Raja Atreya, MD; Koray Tascilar, MD; and Markus Neurath, MD, at Friedrich-Alexander University Erlangen Nuremberg.

 

LINK TO ARTICLE http://dx.doi.org/10.1136/annrheumdis-2021-220597



Filters close

Showing results

110 of 6101
Released: 30-Jul-2021 2:05 PM EDT
Thinking Impaired in 60% of COVID-19 Survivors, Study Finds
University of Texas Health Science Center at San Antonio

In a sample of over 400 older adults in Argentina who had recovered from COVID-19, more than 60% displayed some degree of cognitive impairment, a researcher from The University of Texas Health Science Center at San Antonio reported July 29 at the Alzheimer’s Association International Conference.

Released: 30-Jul-2021 11:50 AM EDT
Support for Government Mandates High and Increasing Over Time, Survey Finds
Rutgers University-New Brunswick

As the coronavirus Delta variant surges throughout the country and mask and vaccine mandates are being considered, a new national survey finds that almost 20 percent of Americans say it is unlikely that they will get the COVID-19 vaccine.

Newswise: How to Play with Your Children in Age-appropriate and Creative Ways When Schools Are Still Closed and Everyone Is Still Stuck at Home
Released: 30-Jul-2021 8:55 AM EDT
How to Play with Your Children in Age-appropriate and Creative Ways When Schools Are Still Closed and Everyone Is Still Stuck at Home
Chulalongkorn University

The COVID-19 situation may have restricted people’s space, but not their imagination. A Chula lecturer has given recommendations to parents who need to spend more time at home on select social activities to enhance children’s development in a safe and age-appropriate way.

Released: 30-Jul-2021 8:30 AM EDT
American Society of Anesthesiologists Strongly Encourages all Health Care Personnel to Get Vaccinated Against COVID-19
American Society of Anesthesiologists (ASA)

Amid the new surge of COVID-19 cases across the U.S., the American Society of Anesthesiologists (ASA), and eight professional societies associated with the specialty, are strongly encouraging the nation’s health care workers and all eligible Americans to get fully vaccinated with one of the COVID-19 vaccines. ASA and the associated societies remind the public that widespread vaccination is the most effective way to reduce illness and death.

Released: 29-Jul-2021 4:45 PM EDT
Which Voices Led Medical Misinformation in the Early Stages of COVID?
University of Cincinnati

In the early and thus far most devastating stages of the COVID-19 pandemic, scientists were at a near loss on how to treat the deadly disease.

Released: 29-Jul-2021 4:40 PM EDT
Half of U.S. Parents May Not Vaccinate Their Youngest Child Against COVID-19
CUNY Graduate School of Public Health and Health Policy

Even as the delta variant of Covid-19 sweeps the globe, leaving those who remain unvaccinated vulnerable, vaccination among adults and teenagers in the United States is stalling, giving rise to concerns over whether parents will vaccinate their young children once vaccines are approved for those under 12 years of age.

Newswise: COVID-19 update: coping with increased cases, breakthrough infections, national masking mandates and vaccine requirements
Released: 29-Jul-2021 4:05 PM EDT
COVID-19 update: coping with increased cases, breakthrough infections, national masking mandates and vaccine requirements
Keck Medicine of USC

Keck Medicine of USC experts speak out on the continued physical and emotional consequences of COVID-19

Released: 29-Jul-2021 3:45 PM EDT
FSMB: Spreading COVID-19 Vaccine Misinformation May Put Medical License at Risk
Federation of State Medical Boards (FSMB)

The Federation of State Medical Boards’ Board of Directors released statement in response to a dramatic increase in the dissemination of COVID-19 vaccine misinformation and disinformation by physicians and other health care professionals on social media platforms, online and in the media.

Newswise: Argonne’s Macal named Fellow of the Society for Computer Simulation International
Released: 29-Jul-2021 2:05 PM EDT
Argonne’s Macal named Fellow of the Society for Computer Simulation International
Argonne National Laboratory

Charles M. “Chick” Macal, a modeling and simulation expert at Argonne, garnered the distinguished title of Fellow of the Society for Computer Simulation International for his 20 years in the field and his recent studies on COVID-19 spread.


Showing results

110 of 6101

close
2.66241